Dataset Information


Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing.

ABSTRACT: Osimertinib, which is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is an important anticancer drug because of its high efficacy and excellent safety profile. However, resistance against osimertinib is inevitable; therefore, therapeutic strategies to overcome the resistance are needed. Doxazosin, a classic quinazoline-based alpha 1-adrenoceptor antagonist is used to treat hypertension and benign prostatic hyperplasia with a known safety profile. The anticancer effects of doxazosin have been examined in various types of malignancies from the viewpoint of drug repositioning or repurposing. However, it currently remains unclear whether doxazosin sensitizes cancer cells to osimertinib. Herein, we demonstrated that doxazosin induced autophagy and enhanced the anticancer effects of osimertinib on the cancer cells and cancer stem cells of non-small cell lung cancer, pancreatic cancer, and glioblastoma at a concentration at which the growth of non-tumor cells was not affected. The osimertinib-sensitizing effects of doxazosin were suppressed by 3-methyladenine, an inhibitor of autophagy, which suggested that the effects of doxazosin were mediated by autophagy. The present study provides evidence for the efficacy of doxazosin as a combination therapy with osimertinib to overcome resistance against osimertinib.


PROVIDER: S-EPMC7460424 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5467531 | BioStudies
2020-01-01 | S-EPMC7330330 | BioStudies
2020-01-01 | S-EPMC7392201 | BioStudies
2017-01-01 | S-EPMC5716361 | BioStudies
2016-01-01 | S-EPMC5349916 | BioStudies
1000-01-01 | S-EPMC6333983 | BioStudies
2020-01-01 | S-EPMC7266273 | BioStudies
2017-01-01 | S-EPMC5355811 | BioStudies
2017-01-01 | S-EPMC5564797 | BioStudies
2018-01-01 | S-EPMC6240476 | BioStudies